Financials

  • Market Capitalization 805.5 M
  • Employee 69
  • Founded 2008
  • CEO N/A
  • Website www.cytomx.com
  • Headquarter Delaware, United States
  • FIGI BBG001J472L3
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-33.83
Price to sales ratio
7.71

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2588
REPL
Replimune Group, Inc. - Common Stock
9.94 USD-9.55%-14.38%+12.83%-13.34%834.41 M USD
2592
IVA
Inventiva S.A. - American Depository Shares
4.30 USD0.00%+11.11%+11.69%+28.74%830.92 M USD
2632
ZVRA
Zevra Therapeutics, Inc. - Common Stock
13.18 USD-1.27%-5.79%+2.89%+23.87%779.14 M USD
2640
SPRY
ARS Pharmaceuticals, Inc. - Common Stock
7.74 USD-2.52%-8.40%-21.42%-15.96%768.61 M USD

Frequently asked questions about CytomX Therapeutics, Inc. - Common Stock

What is the CytomX Therapeutics, Inc. - Common Stock stock price today?

The current price of CytomX Therapeutics, Inc. - Common Stock (CTMX) is 3.7. Over the past 24 hours, the stock has changed by -1.60%. Follow the CTMX chart for real-time price dynamics.

What is the stock ticker of CytomX Therapeutics, Inc. - Common Stock?

CytomX Therapeutics, Inc. - Common Stock trades under the ticker CTMX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is CytomX Therapeutics, Inc. - Common Stock stock going up?

CTMX has changed by -3.90% over the last week, +21.31% over the last month, and +56.12% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was CytomX Therapeutics, Inc. - Common Stock net income for the last quarter?

CytomX Therapeutics, Inc. - Common Stock reported net income of -18.25 M for the last quarter. The previous quarter showed -26.51 M, which means net income changed by +31.17%.

How many employees does CytomX Therapeutics, Inc. - Common Stock have?

As of the latest available data, CytomX Therapeutics, Inc. - Common Stock has 69 employees. Workforce size can provide additional context about the company's scale and operations.

What is CytomX Therapeutics, Inc. - Common Stock EBITDA?

CytomX Therapeutics, Inc. - Common Stock EBITDA is -20.36 M, and its EBITDA margin is -198.49%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy CytomX Therapeutics, Inc. - Common Stock stock?

You can buy CytomX Therapeutics, Inc. - Common Stock (CTMX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in CytomX Therapeutics, Inc. - Common Stock stock?

Investing in CytomX Therapeutics, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CTMX chart and related analysis on metatrader.com as part of your research.

News